Molagri: biopesticides designed against resistance (YC Summer 2026)
Skoor 40 · n = 4 · confidence 0.8 [source]
What they built
Molagri describes its product as "resistance free pesticides" [source]. The company says it designs biopesticides that hit a molecular target unique to pest insects and spare pollinators and beneficial insects [source]. It says it models how pests are likely to evolve so its products stay effective as resistance develops [source]. It is based in Toronto, ON, Canada [source].
Product stage, field data, target crops and regulatory status are not in the evidence.
Record
Measured signals (n = 4):
Founder claims (self-reported, not verified):
Founder names, paper titles, funding, customers and code repositories are not in the evidence.
Why now
The company claims its higher efficacy and bio-based production will reduce emissions in manufacturing and field use [source]. No market timing, regulatory change or customer demand is in the evidence.
Inference: The entity is tagged "energy," but YC lists it under Industrials and Agriculture [source]. Its fit with an energy thesis rests only on the emissions claim.
Unknowns
- Founder identities and which publications are relevant to the product.
- Whether any molecule has been tested in a lab, greenhouse or field.
- The regulatory path for registering the product, and how long it takes.
- Funding raised and runway.
- What "resistance free" means in measurable terms.
Inference: A 4-person team that is hiring after its batch is likely still before product revenue.
Questions for the room
- "Resistance free" is a strong claim. What data shows that your evolution modeling predicts resistance, and over how many pest generations has it been tested?
- Which papers in Nature Communications and Nature Microbiology form the scientific basis for the target, and who on the team led that work?
- What is the emissions reduction per hectare compared with the incumbent pesticide, and is it measured or modeled?
What would move the Skoor
It would rise with named founders tied to relevant publications, field-trial efficacy data or a funded round. It would fall if the target or the resistance modeling has no experimental validation, or if the company's case does not fit the energy thesis.